Everest Medicines has appointed Rogers Yongqing Luo as CEO to lead the next phase of the company’s growth

ShanghaiAnd the September 18 2022 /PRNewswire/- Everest Medicines (HKEX 1952.HK, “Everest”, or “the Company”), a biopharmaceutical company focused on developing and marketing transformational pharmaceutical products to meet critical unmet needs in the Asia Pacific Markets, announced the appointment of Rogers Luo Yongqing as CEO of the company, immediately. Mr. Low will also serve as an Executive Director on the Everest Board of Directors.

Mr. Low brings to Everest over 25 years of healthcare experience with an extensive leadership track record across clinical development, regulatory affairs and marketing. Mr. Lu previously held the position of President and General Manager, Greater China at Brii Biosciences and CEO of TSB Therapeutics where he led rapid registration approval, GMP certification and successful commercialization of the amubarvimab/romlusevimab combination, the first antibody neutralizing COVID-19 treatment in the world. China. Prior to that, he was Global Vice President and General Manager for China at Gilead Sciences where he led the clinical development, regulatory approval and successful commercial launch of eight innovative treatments, efforts that rapidly expanded patient access across China. Mr. Luo previously oversaw the successful launch of several high-ranking medicines. He managed sales, marketing, government affairs and market access functions for several leading multinational pharmaceutical companies including Roche and Novartis, and worked for two years at the Novartis headquarters in Switzerland.

“As Everest Medicines continues to evolve our business strategy and expands our new product pipeline at a rapid pace, we are pleased to have Rogers join the company to lead Everest through its next phase of growth into a fully integrated biopharma company in the ChinaMr. said. Wei FuChairman of the Board of Directors of Everest Pharmaceuticals and CEO of CBC Group. “With his strong background as a senior CEO in both biotech startups and large multinational pharmaceutical companies, Rogers brings to Everest a unique set of expertise including comprehensive scientific vision, proven leadership and excellent marketing capabilities in patient access, and a successful history. Innovative pipeline development in the early and late stages of commercial launch in Greater China. In particular, Rogers’ leadership will enhance new product development and commercial capabilities at Everest as we progress toward potential approvals of late-stage stabilization product candidates, including Nefecon, Xerava, etrasimod and mRNA vaccines. We look forward to leveraging Rogers’ leadership and industry expertise for long-term growth and success throughout the business. “

“I am very excited to join Everest and look forward to working with this talented, world-class team of scientists and industry professionals to advance the company’s industry leadership. We will continue to develop our pipeline in the late stages towards commercialization and with us,” Everest Pharmaceuticals CEO Rogers Yongkin Lu said: With a strong balance sheet, we aim to execute synergistic business development deals to accelerate our path to becoming an integrated biopharma company.” “We will continue to invest in our discovery platform to build an innovative treatment pipeline for the benefit of unmet patients in Greater China and others Asia Pacific markets, creating sustainable and long-term value for our shareholders.”

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on developing and marketing transformational pharmaceutical products that meet the critical unmet medical needs of patients in Asian markets. Everest Medicines management team has deep experience and a proven track record of high quality clinical development, regulatory affairs, CMC, business development and operations in both China And with the world’s leading pharmaceutical companies. Everest Medicines has built a suite of potentially first-in-class or best-in-class universal molecules, many of which are in late clinical development. The company’s clinical areas of interest include oncology, autoimmune disorders, cardiology, nephrology, and infectious diseases. For more information, please visit her website at www.everestmedicines.com.

Forward-looking statements:

This press release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief, or current expectations of the Company or its officials with respect to the Company’s business operations and financial condition, which may be identified by terms such as “will”, “expect”, “expect” , “future”, “intends”, “plans”, “believes”, “estimates”, “confident” and similar statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties or other factors, some of which are outside the Company’s control and are unforeseen. Therefore, actual results may differ from those contained in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, the competitive environment, and political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors, or representatives are under no obligation nor obligation to revise forward-looking statements to reflect new information or future events or conditions after the date of this press release, except as required by law.

Cision

Cision

View original content:https://www.prnewswire.com/news-releases/everest-medicines-appoints-rogers-yongqing-luo-as-chief-executive-officer-to-lead-next-stage-of-company-growth-301626689. programming language

SOURCE Everest medicines

Leave a Comment